Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
NE

NASDAQ · NERV

Minerva Neurosciences, Inc.

Healthcare · Biotechnology

$3.43

Up+$0.11 (+3.31%)

Updated Oct 7, 2026, 3:01 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.95M
P/E ratio
2.79
Dividend yield
0.00%
52-week range
$2.08 – $12.46
Volume
105.31K
Avg. volume
3.01M

Price performance · NERV

NERV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

NERV closed at $3.43 after 21 trading sessions, down 21.51% for the selected period.

Last close
$3.43
Period change
-21.51%
Period low
$3.23
Period high
$4.37
Daily close
View OHLC price history
NERV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$3.38$3.49$3.28$3.43105.31K
Oct 5, 2026$3.30$3.56$3.19$3.3272.36K
Oct 2, 2026$3.29$3.365$3.22$3.2857.02K
Oct 1, 2026$3.35$3.35$3.17$3.2389.22K
Sep 30, 2026$3.37$3.48$3.31$3.3579.32K
Sep 29, 2026$3.50$3.50$3.27$3.3533.34K
Sep 28, 2026$3.37$3.435$3.23$3.4062.25K
Sep 25, 2026$3.46$3.50$3.37$3.40103.31K
Sep 24, 2026$3.51$3.61$3.33$3.45147.5K
Sep 23, 2026$3.78$3.78$3.45$3.49130.46K
Sep 22, 2026$3.71$3.861$3.66$3.81123.93K
Sep 21, 2026$3.72$3.81$3.59$3.685148.62K
Sep 18, 2026$3.46$3.7996$3.43$3.66815.43K
Sep 17, 2026$3.56$3.635$3.44$3.46229.11K
Sep 16, 2026$3.83$3.88$3.48$3.485224.51K
Sep 15, 2026$4.01$4.05$3.57$3.83287.17K
Sep 14, 2026$4.30$4.385$3.98$4.01119.44K
Sep 11, 2026$4.24$4.375$4.13$4.15135.95K
Sep 10, 2026$4.10$4.235$4.10$4.1672.1K
Sep 9, 2026$4.35$4.4277$4.10$4.12112.06K
Sep 8, 2026$4.40$4.4585$4.32$4.3791.83K

Latest NERV news

The latest Smart Investors Daily articles mentioning NERV.

Stock researchCompany · Overview

NERV research

Overview

Company profile and research snapshot.

Company profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
NERV recent ratings
DateFirmRatingTarget
Aug 14, 2026JefferiesBuy—
Apr 15, 2026CitizensMarket Outperform—
Mar 12, 2026HC Wainwright & Co.Neutral—
Nov 6, 2025HC Wainwright & Co.Neutral—
Feb 26, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside cha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By